attana - sensor technologies


Aggregation can be a consequence of a disease, the effect of a drug, or result from inefficiencies of manufacturing processes. To determine aggregation in biologics with high sensitivity and efficiency is important for improved development of biologics, which can easily be done with the Attana biosensors. 

Attana’s biosensors based on QCM technology are, due to their high sensitivity to mass changes, a powerful tool to determine aggregation. Together with the applied protein service group at Lonza, UK, Attana has developed assays to characterize aggregation of biologics. These assays are efficient tools for improving antibody development to avoid aggregation or to study the impact of small molecules on protein aggregation.

The first aggregation assay, “Off-rate”, considers the dissociation rate. The more aggregated the molecules the slower the dissociation, due to avidity and rebinding.  In the second assay, “Secondary antibody”, the sample molecule is captured on the surface.  More aggregation gives more epitopes available for a secondary antibody to bind and thus a higher signal is obtained. The third assay, “Capturing”, captures sample on the surface until saturation is reached. The more aggregated, the higher the signal. All three assays display good respective agreement with Lonza’s Oligomer Detection Assay (ODA) technology. Benefits of the assays presented are the ease of use and the providing of high throughput. For more information, please contact us.